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was performed. Cronbach’s alpha coefﬁcients and Pearson’s
product moment correlations were calculated to estimate relia-
bility. To establish construct validity, correlation coefﬁcients
were calculated between the subscales and vitality, well-being,
treatment satisfaction, and/or baseline glycosylated hemoglobin
(HbA1c). Standard errors of measurement (SEMs) were calcu-
lated to estimate minimal important difference. RESULTS: In
both studies: 1) factor analysis conﬁrmed the factor structure of
the four subscales with the exception that the “sleepiness or
drowsiness” item loaded with the Fatigue subscale items rather
than the Cognitive Distress items; 2) test-retest reliability (all
>0.68) and Cronbach’s alpha coefﬁcients (all >0.79) were accept-
able; 3) associations between subscales and other patient-
reported outcomes measures and/or HbA1c were signiﬁcant (p <
0.05) and in the hypothesized directions; and 4) SEMs were
approximately 0.5 on a 1 to 5 scale. CONCLUSION: Prelimi-
nary validation indicates that the Cognitive Distress, Fatigue,
Hyperglycemia, and Hypoglycemia subscales are potentially reli-
able and valid individual measures for use in clinical trials eval-
uating antihyperglycemic medications in patients with type 1 or
type 2 diabetes.
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OBJECTIVES: This study reports relationships between two
instruments of health status and an instrument of quality of life
(QoL) in a cross-sectional study among patients with Type 2 Dia-
betes Mellitus (T2DM). METHODS: Of generic health status
(SF-12 and EuroQoL EQ-5D), and diabetes-speciﬁc QoL (Audit
of Diabetes Dependent Quality of Life–ADDQoL). Patient
reported data were merged with retrospective clinical data
including A1C, comorbidities, diabetes complications score,
BMI, and others, from electronic medical records. RESULTS:
Usable response rate was 44.3% (n = 385). Mean A1C of respon-
dents was 7.2 (+1.4), mean diabetes duration was 10.2 (+9.1)
years, and 62.1% were obese (BMI >30). About 49% of respon-
dents were on oral medications only, 31.7% on oral medications
and insulin, and 9.4% on insulin only. Spearman correlations of
the EQ-5D were 0.640 with the SF PCS-12, 0.534 with the SF
MCS-12, and 0.316 with the ADDQoL (all p < 0.001). Insulin
use and diabetes-related complications were signiﬁcantly associ-
ated with poorer scores on all measures. Only ADDQoL scores
were signiﬁcantly better among those with the ADA recom-
mended A1C level <7.0 (p = 0.002). Nearly 73% respondents
reporting moderate problems with mobility and usual activities
on the EQ-5D were clinically obese. Obesity signiﬁcantly
impaired SF-12 scores but not ADDQoL scores. A path analytic
model relating SF-12 scores with EQ-5D and ADDQoL scores
had good ﬁt (Chi sq. = 1.32, p = 0.250; TLI = 0.99; RMSEA =
0.03). CONCLUSION: All three measures discriminated on the
basis of diabetes treatment group and number of complications.
Health status was impaired by obesity in T2DM. Those patients
with poorer glycemic control had lower scores on the disease-
speciﬁc QoL instrument. The health status and QoL instruments
used in the study appeared to measure different constructs, con-
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OBJECTIVES: To compare self-report measures of medica-
tion adherence with claims-based measures of adherence.
METHODS: A mail survey was conducted of persons with dia-
betes in the Henry Ford Health System in 2006. Prescription
claims were obtained for survey respondents, and the analyses
were conducted with 932 persons who were using at least two
oral medications for diabetes. The self-reported measures of
adherence included a six-category self-rating of adherence which
ranged from “never” to “all of the time” and a visual analog
scale (VAS) wherein patients marked the percentage of time that
they followed the medication regimen as directed The claims-
based measure was the continuous measure of availability
(CMA) reported as a scale from 0 to 100%. Two dichotomous
measures of adherence were created: CMA-80 (CMA cut at
80%); VAS-80 (VAS cut at 80%). RESULTS: The VAS and CMA
demonstrated a linear relationship in the expected direction with
the self-selected categories for medication adherence. The mean
VAS scores ranged from 62.4% to 98.1% across the categories
(F = 180.4, p < 0.001), and the CMA ranged from 66.1% to
85.4% (F = 15.8, p < 0.001). The VAS had a moderate correla-
tion with the CMA (r = 0.25). The mean (±SD) for the VAS and
CMA were 95.5 (±10.4) and 83.2 (±15.9), respectively. For dif-
ference scores (VAS minus CMA), 33.5% of respondents had a
VAS that was at least 1 SD higher than CMA. When comparing
the VAS-80 to the CMA-80, the area under the ROC curve was
0.54 (2.3% were categorized as adherent by CMA-80, but non-
adherent by VAS-80; 30.2% were categorized as non-adherent
by CMA-80, but adherent by VAS-80). CONCLUSION: Self-
reported adherence to medications by patients with diabetes is
moderately correlated with claims-based estimates. However,
about one-third of respondents will have a VAS that is signiﬁ-
cantly higher than CMA.
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OBJECTIVES: To evaluate medication adherence of select lipid
lowering and oral anti-diabetic medications in diabetic patients
during the Medicare Part D beneﬁt coverage gap. METHODS:
This was a retrospective evaluation of pharmacy claims data-
base. The evaluation consisted of standard Medicare Part D
beneﬁt patients at an 185,000 member managed care organiza-
tion during January 1, 2006 through November 30, 2006. Study
patients included anyone who encountered claims for both a 
3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor
(statin) and an oral (PO) anti-diabetic medication during January
2006, and reached the coverage gap by November 30, 2006.
Patients were excluded if they subsequently experienced cata-
strophic coverage or did not reach the coverage gap during 2006.
Medication adherence was measured using pharmacy claims
data to calculate medication possession ratios (MPR). A descrip-
tive comparison of MPR during “pre-coverage gap days” and
